ABOS Acumen Pharmaceuticals, Inc.
$2.92▲ +2.10%
Healthcare
Other
After hours
$2.93▲ +0.34%
Sep 11, 7:30 PM ET
Volume 318.2K
Avg Volume (10D) 322.0K
Key Metrics & Fundamentals
Market Cap
$211.17M
P/E Ratio
–
Div Yield
–%
52W Range
1.21 - 3.60
% vs 50 MA
11.74%
% vs 200 MA
18.19%
RSI-14
53.4
MACD Histogram
-0.0300
Beta (1Y vs SPY)
1.94
Free Cash Flow
-$18.08M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$31.42M
COGS
–
Operating Exp
$32.56M
Operating Income
-$32.56M
EBIT
-$32.56M
Pretax Income
-$32.72M
Net Income
-$32.72M
EPS (Diluted)
-0.45
Price & Volume History
Loading chart…
Recent News
Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026
GlobeNewswire · Sep 10, 2026 8:00 PM
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
GlobeNewswire · Sep 2, 2026 8:00 PM
Acumen Pharmaceuticals Inc (ABOS) (Q2 2026) Earnings Call Highlights: Advancing Sabirnetug ...
GuruFocus.com · Aug 12, 2026 11:04 PM
Acumen Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
Moby · Aug 12, 2026 4:56 PM
Acumen Pharmaceuticals Q2 Earnings Call Highlights
MarketBeat · Aug 12, 2026 1:03 PM
Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights
GlobeNewswire · Aug 12, 2026 11:00 AM
Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026
GlobeNewswire · Aug 5, 2026 8:00 PM
VERAXA Biotech Shows Regulatory Progress on Cancer Therapy Platform
Exec Edge · Jul 20, 2026 4:15 PM
Slate Medicines Appoints Mark W. Hahn to Board of Directors
Exec Edge · Jul 16, 2026 4:18 PM
All You Need to Know About Acumen Pharmaceuticals (ABOS) Rating Upgrade to Buy
Zacks · Jul 15, 2026 4:00 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See ABOS's money flow as a full page
Social Sentiment
No Reddit posts found for ABOS.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.